115 results on '"Apter Dan"'
Search Results
2. Pooled efficacy results of estetrol/drospirenone combined oral contraception phase 3 trials
3. RF34 | PMON202 The Human Metabolic Profile of Estetrol
4. Association of Chlamydia trachomatis infection with cervical atypia in adolescent women with short-term or long-term use of oral contraceptives: a longitudinal study in HPV vaccinated women
5. Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial
6. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials
7. Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland
8. Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women
9. Immunogenicity, Efficacy, Effectiveness and Overall Impact of HPV Vaccines
10. Sexuality Education: Finnish and Chilean Experiences
11. Adolescent Contraception
12. Comparative pharmacokinetic analysis of levonorgestrel-releasing intrauterine systems and levonorgestrel-containing contraceptives with oral or subdermal administration route
13. 1239. Different Dose Levels of a Respiratory Syncytial Virus Maternal Vaccine Candidate (RSVPreF3) Administered to Non-pregnant Women in a Randomized Clinical Trial Are Immunogenic and Well Tolerated
14. An alternative term to make comprehensive sexuality education more acceptable in childhood
15. Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase
16. Oestrogen-free oral contraception with a 4 mg drospirenone-only pill: new data and a review of the literature
17. Verbal and Behavioral Expressions of Child Sexuality Among 1–6-Year-Olds as Observed by Daycare Professionals in Finland
18. Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied
19. Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women
20. Effectiveness of the AS04‐adjuvanted HPV‐16/18 vaccine in reducing oropharyngeal HPV infections in young females—Results from a community‐randomized trial
21. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years
22. Is the risk of cervical atypia associated with the interval between menarche and the start of sexual activity? A population-based cohort study
23. International Perspectives: IUDs and Adolescents
24. Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials
25. Efficacy of the 1-Year Segesterone Acetate/Ethinyl Estradiol Contraceptive Vaginal System [21OP]
26. Corrigendum to “Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use” [Eur J Obstetr Gynecol Reprod Biol 210 (2017) 22–28]
27. Moderate Coverage Vaccination Eradicates Oncogenic Human Papillomaviruses if a Gender-Neutral Strategy is Applied
28. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III)
29. Contraception options: Aspects unique to adolescent and young adult
30. Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II)
31. Vaccination protects against invasive HPV‐associated cancers
32. The risk of cervical atypia in oral contraceptive users
33. Overcoming barriers to levonorgestrel-releasing intrauterine system placement: an evaluation of placement of LNG-IUS 8 using the modified EvoInserter ® in a majority nulliparous population
34. Impact of gender‐neutral or girls‐only vaccination against human papillomavirus—Results of a community‐randomized clinical trial (I)
35. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up ofthree cohorts from randomized trials
36. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control
37. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use
38. Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: Interim analysis of a large community-randomized controlled trial
39. Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults—Randomized Controlled Trial
40. Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA)
41. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant
42. A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents
43. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases
44. Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination
45. The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial
46. Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial
47. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial
48. Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine – a pilot study
49. Prevention of HPV Disease Burden
50. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.